CA-PERSONALIS,-INC.
18.11.2020 14:02:04 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy , a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
Poster Number |
Title & Presenter |
Dates |
||
40
|
Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
|
NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
Title |
Title & Presenter |
Dates |
||
Sponsored Symposia |
NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
|
NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck Debuts New Family Bundle Ticket Options13.7.2026 22:30:00 CEST | Press release
Groups of four can save up to 20% on Observation Deck tickets purchased online The Empire State Building Observation Deck (ESBOD), atop the “World’s Most Famous Building,” announced today new ticket bundle options for families of all ages to save on their visit to the famed New York City landmark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713003884/en/ Empire State Building Observation Deck Debuts New Family Bundle Ticket Options Groups of four who purchase the new Family Ticket Bundle can save up to 20 percent on tickets to the Empire State Building’s iconic 86th and 102nd Floor Observation Decks, with options for express access and flex admission. The Family Ticket Bundle is available online only. “The Empire State Building Observation Deck is one of the best activities for families in NYC with immersive, educational museum exhibits and Manhattan’s best skyline views,” said Dan Rogoski, observatory general manager.
Kinaxis Inc. to Host Second Quarter 2026 Financial Results Conference Call on August 6, 202613.7.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that it has scheduled a conference call to discuss its financial results for the second quarter ended June 30, 2026. The call will be hosted on Thursday, August 6, 2026, at 8:30 a.m. Eastern Time by Razat Gaurav, Chief Executive Officer, and Peter Yaraskavitch, Vice President, Financial Planning and Analysis, followed by a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Wednesday, August 5, 2026. CONFERENCE CALL DETAILS DATE: Thursday, August 6, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/854228135 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietar
PagerDuty Announces Arnaud Lagarde, Vice President of EMEA13.7.2026 22:05:00 CEST | Press release
PagerDuty, Inc. (NYSE: PD), a leader in AI-first operations management, today announced the appointment of Arnaud Lagarde as vice president of EMEA. Lagarde will lead PagerDuty’s next phase of growth in the EMEA region, bringing the entire incident management lifecycle to customers across EMEA to solve their biggest digital challenges. “We are thrilled to appoint Arnaud as vice president of EMEA, since he brings a wealth of enterprise sales relationships and years of experience growing this region,” said Todd McNabb, chief revenue officer at PagerDuty. “Arnaud brings a specific combination of deep technical expertise and leadership that will be critical for PagerDuty’s customers, partners and employees. He is a great fit for PagerDuty and we look forward to his impact.” Lagarde brings to the role over 20 years of experience spanning companies like Automation Anywhere, CA Technologies and BMC. Over the past two decades, he has worked closely with founders, investors and executive teams
Samos Energy Acquisition Corporation Announces Closing of $230 Million Initial Public Offering13.7.2026 21:42:00 CEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the closing of its initial public offering (“IPO”) of 23,000,000 units, including the full exercise by the underwriters of their overallotment option to purchase an additional 3,000,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds to the Company of $230,000,000. The units began trading on the New York Stock Exchange (the “NYSE”) under the ticker symbol “SAMO.U” on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Of the proceeds received from the consummation of the initial public offerin
Kina, EU-respondenter optimistiske om fremtidsudsigterne for samarbejde: GT survey13.7.2026 20:46:00 CEST | Pressemeddelelse
Kina og EU har haft etablerede diplomatiske forbindelser i mere end et halvt århundrede. Fra etableringen af formelle diplomatiske forbindelser til udviklingen til et omfattende strategisk partnerskab er Kina-EU-forbindelserne blevet et af de mest indflydelsesrige bilaterale forhold i verden i dag. Ud over Kina gennemførte Global Times Institute (GTI) fra den 16. oktober til den 4. november 2025 en spørgeskemaundersøgelse i 20 EU-medlemsstater, herunder Danmark, Sverige, Spanien, Belgien og Tyskland, ved hjælp af 21 sprog som spansk, fransk, tysk og kinesisk. Mere end 16.300 gyldige spørgeskemaer blev indsamlet. Undersøgelsesdataene viser, at et flertal af befolkningen i både Kina og EU er interesserede i hinandens kulturer, har stor tillid til fremtiden for det kinesisk-europæiske økonomiske og handelsmæssige samarbejde, og støtter styrket samarbejde mellem Kina og EU inden for global styring. Høj grad af bevidsthed og vilje til kommunikation Denne undersøgelse viser, at befolkningen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom